Product News
Quanterix granted Breakthrough Device designation from U.S. FDA for blood-based pTau-181 assay for Alzheimer’s Disease
The FDA’s Breakthrough Device designation is granted to products that have the potential to offer a more effective diagnosis of life-threatening diseases